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Bulleted statements  
 What’s already known about this topic? 
Disparities in healthcare provisions and outcomes have been noted in several 
medical areas. Little is known about dermatology. Data from Medicare in the United 
States, indicated financial and racial barriers to receipt of biologic therapies in 
psoriasis. 
 
 What does this study add? 
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We documented inequalities of drug prescriptions for psoriasis in Italy, with a trend 
towards a higher frequency of prescription for more expensive biologics in higher 
socio-economic sectors of the population. 
 
Abstract 
Background: Limited evidence is available on the impact of socioeconomic factors in drug 
prescriptions for psoriasis. 
Objectives: To investigate factors influencing prescription of conventional versus biological 
treatment for psoriatic patients, based on the Psocare registry with a special focus on 
socioeconomic factors. 
Methods: This was a cross-sectional study evaluating the baseline data of patients included 
in the Italian Psocare Registry. All of the consecutive adult patients with a diagnosis of 
chronic plaque psoriasis (Ps) or psoriatic arthritis and who were prescribed a systemic 
treatment for Ps at the participating centres were included in this study. Univariate and 
multivariate analyses of the baseline factors associated with a biologics prescription were 
performed. 
Results: From September 2005 to September 2009, 12,838 patients were identified. A 
multivariate analysis revealed that, among other factors, completing a level of education 
higher than lower secondary school and being employed as a manager or a professional 
were independent factors associated with a biologics prescription at entry in the registry. 
Additional analyses on the association between these two variables and a severe Ps 
condition (i.e., psoriasis area and severity index [PASI] score > 20) revealed a significant 
increasing trend of severe disease towards lower educational attainment, while 
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unemployed patients were more likely to have a more severe condition as compared to the 
other categories of workers. 
Conclusions: We documented inequalities of drug prescriptions for Ps in Italy, with a trend 
towards a higher frequency of prescription for more expensive biologics in higher socio-
economic sectors of the population. 
 
INTRODUCTION 
Inequalities in health can be defined as unfair systematic differences in the healthcare and 
the health status among individuals.1,2 Disparities in healthcare provisions and outcomes 
(i.e., morbidity and mortality) have been noted, for example, between different social 
groups, between urban and rural populations and between different geographical areas in 
the same country.3,4 Much of these discrepancies cannot be accounted for on biological 
grounds. Instead, the major part is played by socioeconomic and environmental factors, 
including lifestyles.  
Several treatment options are available for Ps. The annual cost of these treatments shows 
large variations. In particular, more targeted therapies, including biological agents (such as 
TNF-alpha-blockers), are very expensive, and their prescription is restricted to patients not 
responding or having contraindications to less expensive conventional agents.  
To date, only two studies from the United States have focused attention on the impact of 
socioeconomic factors on drug prescriptions in Ps. One study from the Medicare social 
insurance program documented that people without access to a Medicare Part D low-
income subsidy had a much lower chance of having received biologics than those with such 
an access.5 Another study limited to a single academic medical centre, documented that 
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difficulty in obtaining biologics was associated with younger age, lower income level and 
lack of insurance.6 
The aim of our study was to investigate the factors influencing the prescription of 
conventional treatments versus biological treatments for psoriatic patients, based on the 
PSOCARE registry, with a special focus on socioeconomic factors, which may reflect 
inequalities in healthcare. The PSOCARE registry systematically recruits all of the patients at 
the reference centres who are starting a new systemic treatment for Ps in Italy.7 
 
METHODS 
This was a cross-sectional study evaluating the baseline data of the patients who were 
included in the Italian Psocare Registry. In this study, 155 dermatology outpatient clinics 
participated. These clinics were located across Italy and were appointed by the Italian 
Regional Health Authorities (see Appendix) as reference centres for the treatment of 
moderate-to-severe Ps. The Italian National Health Service (NHS) was established in 1978 
and it is founded on the principles of universal coverage, social financing through the use of 
general taxation, and non-discriminatory access to the health care services.8 
The study was conducted according to the Declaration of Helsinki and got the ethics 
committees approval of the participating centres. The Italian Psocare Registry’s goals and 
methods have been described in detail elsewhere.7 
The main outcome of this study was to describe the factors associated with the choice of 
systemic treatment at entry in the registry. 
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Patients 
All consecutive adult patients (aged ≥ 18 years) who were clinically confirmed with a 
diagnosis of chronic plaque Ps or psoriatic arthritis (PsA) and who were prescribed a new 
systemic treatment for Ps for the first time in their life at the participating centres were 
included in this study. To get reimbursement by the NHS, a compulsory registration within 
the Psocare registry was required for subjects receiving a biological therapy. On the 
contrary, conventional treatment could also be prescribed outside the registry. 
The conventional treatments that were considered included acitretin, cyclosporine, 
methotrexate and PUVA therapy, while etanercept, infliximab, adalimumab and 
ustekinumab were considered as biological treatments.  
According to the registered indications, only the patients with moderate-to-severe Ps 
(psoriasis area severity index - PASI > 10) with failure, contraindication or adverse events to 
conventional systemic agents (e.g., cyclosporine, acitretin, methotrexate and PUVA) were 
eligible for biological therapy (e.g., infliximab, etanercept and adalimumab). The patients 
receiving combination treatments or off-label dosages and the patients who had unspecified 
baseline treatments were excluded from this study. All of the patients gave written 
informed consent before being included in this study. 
 
Data collection 
The study investigators registered the patients on a web-based electronic data collection 
system endowed with internal quality controls, which also guaranteed confidentiality. The 
data collected at the baseline included: 1) demographic details and personal habits (e.g., 
smoking, average alcohol consumption, educational attainment and employment status); 2) 
a history of current or previous main comorbidities and medications; 3) a dermatological 
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and family history of Ps and/or PsA; 4) the severity of Ps, any drugs prescribed and the 
results of the laboratory tests performed before the prescription. The PASI was adopted as 
the measure of disease severity. In addition the perceived patient’s severity was rated 
between 0 and 10 by using a standard visual analogue scale (VAS). The Charlson comorbidity 
index (CCI) was also used as a surrogate measure for overall comorbidity.  
 
Statistical analysis 
For descriptive purposes, data are presented as means with standard deviations (SDs) or 
numbers with percentages for the continuous and categorical variables, respectively. 
The continuous variables were categorised, for analysis purposes, using clinically meaningful 
thresholds as cut-offs. A univariate analysis of the baseline factors associated with a 
biologics prescription was performed by means of a Pearson’s χ2 test. In the case of ordinal 
data, a Cochran–Armitage test for linear trend was also performed across different levels of 
variables.  
All of the variables with a p-value < 0.10 from the univariate analysis were considered for 
inclusion in the multivariate analysis. A multiple logistic regression with a forward stepwise 
algorithm selection was used to identify the significant predictors of a biological 
prescription. The effects of the identified factors were expressed in terms of an odds ratio 
(OR), along with a 95% confidence interval (CI) and a p-value. When required, the effect of 
interaction between selected variables was tested as well. Multiple logistic regression 
models were also used to adjust the effects of selected factors on severe Ps conditions (PASI 
score > 20). Patients with missing data were excluded from the analysis. When planning this 
study we considered that with 12,838 patients fulfilling inclusion/exclusion criteria at the 
time of data extraction we could detect OR >1.18 in multiple logistic regression models 
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(ratio of control and case group of 1.35, proportion of exposure in control group >10%, 
multiple correlation coefficient <0.3, α=0.05, β=0.2). 
In addition, the association among the variables were analysed by means of an artificial 
adaptive system, the auto semantic connectivity map (AutoCM).9 AutoCM is a data mining 
tool based on an artificial neural network (ANN) model that is especially effective at 
highlighting any patterns and/or systematic relationships and hidden trends among 
variables. The weights determined by AutoCM are proportional to the strength of the 
associations across all of the variables. The weights are transformed into distances, and a 
mathematical filter (i.e., the minimum spanning tree [MST])10 is applied to the matrix of the 
distances. A connectivity map is then generated from the MST. In the connectivity map, 
hubs of variables are detected, and related dependent variables converge to these hubs. 
The system also provides a quantification of the strength of links among variables by a 
numerical coefficient ranging from zero, minimum strength, to 1, maximal strength. All of 
the tests were considered significant at a p-value < 0.05. Analyses were performed with 
SPSS software, version 20 (IBM Corp.) and AutoCM software, version 7 (Semeion). 
 
RESULTS 
Overall, from September 2005 to September 2009, 12,838 patients fulfilling the study 
inclusion criteria were identified. The general characteristics of the patients are reported in 
Table 1. The mean age was 48.8 ± 14.4 years (mean ± SD), with a male:female ratio of 1.9. 
The mean BMI was 27.0 ± 4.9 kg/m2, and the prevalence of smokers and regular drinkers 
was 40.2% and 35.7% respectively. Most patients were married (70.7%), had attained lower 
or upper secondary education (33.3% and 38.9% respectively) and worked as employees, 
craftsmen or skilled workers (32.5%). The mean PASI score was 17.2 ± 10.5, with an average 
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disease duration of 16.9 ± 13.0 years and a mean CCI of 0.29 ± 0.78. PsA and pustular Ps 
were present in 24.8% and 2.9% of the patients, respectively. Prescribed drugs at entry in 
the registry were etanercept (29.0%), cyclosporine (27.3%), acitretin (14.7%), methotrexate 
(11.7%), infliximab (8.8%), adalimumab (4.9%) and PUVA therapy (3.8%). The overall rate of 
biological drug prescriptions was 42.5%. 
 
Analysis of variables associated with biological drug prescriptions 
All of the factors with a p-value <0.10 in the univariate analysis (Table 1) were evaluated for 
inclusion in the multivariate model. These factors were age, BMI, smoking and drinking 
habits, marital status, geographical area, educational attainment, present or last 
occupation, calendar year of first visit, PASI score, patient’s perceived severity, disease 
duration, a history of hypertension, hyperlipemia, chronic liver diseases, neoplasms, the 
presence of pustular Ps or PsA, the number of previous systemic treatments for Ps, hospital 
admissions for Ps in the last 5 years and previous clinical remissions for Ps. 
A multivariate analysis revealed that an age lower than 60 years, a BMI greater than 25 
kg/m2, an ex-/non-smoker or ex-/non-drinker status, being visited in central/southern Italy, 
an educational attainment higher than lower secondary school, employment as a manager 
or a professional, the calendar year of visit (with a significant increasing trend over time), a 
PASI score greater than 10, a positive history of hypertension or a negative history of 
neoplasms, the absence of pustular Ps or the presence of PsA, the number of previous 
systemic treatment for Ps (with a substantial growing trend with increasing numbers) and 
any hospital admission for Ps in the last 5 years were all associated with biologic 
prescriptions at entry in the registry. Interestingly, educational attainment showed to be an 
independent predictive factor, with a clear increasing trend of biological drug prescriptions 
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towards higher education. This was also confirmed by a higher employment status. 
Additional analyses on the association between these two variables and a severe Ps 
condition (PASI score > 20) revealed a significant increasing trend of severe disease towards 
lower educational attainment, while unemployed patients were more likely to have a more 
severe condition as compared to other categories of workers, including managers and 
professionals (Table 2). Furthermore we assessed the interaction between the geographical 
area and both the employment status and the educational attainment. While the first was 
not significant the latter was an effect modifier for the prescription of biologicals, with 
education having more impact on the outcome in the northern area compared to 
central/southern regions (data not shown). 
 
AutoCM analysis 
The Figure shows the map produced by the AutoCM algorithm. The algorithm highlights the 
main associations between variables in the database, offering a simple graphical way to 
display their mutual interaction. The resulting map can be divided into three regions. In the 
first and second regions, at the top and at the bottom, the variables are connected to 
conventional and biological drug prescriptions, respectively, at entry in the registry. Both of 
the variables act as main hubs in the system. Being a smoker or a drinker, being 60 years old 
or more, being overweight or obese, having any history of main comorbidities (except for 
chronic liver diseases or a short duration of disease) and being fairly naïve to systemic 
treatments were all factors connected to conventional prescriptions. Unskilled workers and 
those with primary or lower secondary school degrees were associated, as well, to 
conventional drug use. These results confirmed those of the main analysis. 
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Conversely, at the bottom of the map, having severe Ps or mild Ps associated with PsA, 
being a non-responder to previous systemic treatments or being admitted at a hospital for 
Ps in the last 5 years were all associated with biological prescriptions. In addition, being a 
manager or having at least a university degree was confirmed to be associated with 
biological drug use. 
Finally, the middle region of the map captures other less relevant pieces of information, 
which are common to most of the patients included. 
 
DISCUSSION 
Targeted biological therapies have represented a breakthrough in the management of 
patients with Ps. These drugs are much more expensive than conventional agents, and their 
use is restricted to patients with contraindications or side effects to these agents. The aim 
of our study was to investigate the determinants that influenced the prescription of 
systemic conventional treatments versus biological treatments for moderate-to-severe 
psoriatic patients based on data from the PSOCARE registry. In our study, less than half of 
the patients received a biological treatment for their Ps. We documented an increasing 
trend in the number of prescriptions of biological agents with a higher education and 
employment status of the patients. Conversely, unemployed patients and patients with 
lower educational attainment were less likely to receive a prescription of a biological agent. 
These differences were not accounted for by other factors, such as disease severity or 
lifestyle issues. As a matter of fact, the unemployed and less educated patients had a higher 
chance of presenting at the baseline with a more severe cutaneous condition (PASI score 
>20) as compared to the other patients. A similar result was found in a study of Horn et al.,11 
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where patients with severe psoriasis were more likely to have lower household income, 
although information on severity and income was self-reported by the patient. 
Our results were confirmed in a secondary analysis performed by using ANN systems. The 
main advantage of this analysis is the possibility of presenting, in a single map, the mutual 
associations among all the variables in the registry. A possible disadvantage, however, is 
that the higher complexity of the model, compared to the classical approach used in the 
main analysis, requires a larger sample size in order to achieve sufficient generalizability of 
results. 
Socio-economic status (SES) is traditionally composed of three dimensions: educational 
attainment, occupation and household income. Education in combination with occupation 
are the most frequently used indicators. Household income may be difficult to obtain due to 
privacy restriction. It has been shown, however, that higher levels of education are 
associated with better economic outcomes,12 while the occupational status reflects the 
educational attainment required to obtain the job and income levels, so that it encompasses 
both income and educational attainment.13 In our study, we didn’t collect other variables 
which may contribute to the definition of wealth such as household income, family size, 
religion and ethnicity.  
A significant trend for the penetration of biologicals over time was observed from 2005 to 
2009 in our registry, but the increased penetration did not temper the effect of inequalities 
in biologicals prescription. 
The Italian NHS is expected to guarantee uniform care throughout the country. Public 
healthcare spending, in the last 25 years, has consistently exceeded central government 
forecasts, and the expectation is that the resources are allocated fairly in a way to warrant 
equal access to care for all of the individuals registered for it.14 Even if it is understandable 
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that the information about new therapies could be more available to those people who are 
younger, those people with a higher level of education and those with a higher 
socioeconomic status, it is not expected that those factors could influence prescriptions by 
treating physicians. It can be also hypothesized that higher socioeconomic status and 
education might be associated with better patients’ negotiation skills or increased empathy 
from physicians, although further research is needed to clarify these points. 
It should be noted that in our study, all of the consecutive patients receiving a first 
prescription of a new systemic agent and being seen at a network of dermatological centres 
were enrolled, and a selection bias is unlikely.15  
Health inequities have been defined as systematic unfair differences in care that is 
preventable by a reasonable action.16 Inequalities have been documented in clinical care for 
selected skin conditions, such as skin cancer and atopic dermatitis.3,17-23 Two previous 
experiences from the United States, have documented the impact of socioeconomic factors 
on drug prescriptions in Ps. One study from the Medicare program showed that people 
without access to a Medicare Part D low-income subsidy had a 70% lower odds of receiving 
biologics than those with such an access. A similar low chance was also observed for black 
patients compared with white patients.5 Another study limited to a single academic medical 
centre, documented that difficulty in obtaining biologics was associated with younger age, 
lower income level and lack of insurance.6 Interestingly, a study based on data from the 
PsoReg registry in Sweden, documented that patients with psoriasis had fewer 
opportunities to access biological medications as they age.24 The study made adjustment for 
educational level but not for income.  
In agreement with data from the two studies from the United States, we documented 
disparities of care in Ps in Italy, with the prescription of biological agents being more 
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frequent in higher socio-economic sectors of the population. We did not assess if a disparity 
of a prescription translated into differences in the clinical outcome or co-morbidities over 
time. Such an issue should be considered in future studies.  
Ideally, everybody should expect an identical standard of care. The aim of policy for equity is 
to reduce or eliminate those disparities, which are considered to be both avoidable and 
unfair.4 There are some possible actions to reduce inequalities in healthcare provisions for 
psoriatic patients, including patient education and auditing of clinical decisions. Recently, 
the American Academy of Dermatology (AAD) created the Access to Dermatologic Care Task 
Force (ATDCTF) to foster the consciousness of dermatologists about the disparities affecting 
minority populations because of race or ethnicity, socioeconomic status, geography, gender, 
age and disability status and to cultivate policies that improve these people’s access to 
dermatological services.3 Similar actions should be implemented in other countries as well.  
To summarise, we documented the inequalities in drug prescriptions for Ps in Italy with a 
trend towards a higher number of prescriptions for more expensive biologics in higher 
socio-economic sectors of the population. This is unfair considering that drugs are paid for 
by the money of the National Health System in which all Italian citizens contribute. 
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Figure -  AutoCM map of selected variables at entry in the registry. 
Legend: The map shows the association among the variables and can be divided into three 
regions: The first region at the top (dotted line) and the second region at the bottom 
(dashed line) show information connected to conventional and biological drug prescriptions 
at entry into the registry; the last region in the middle (dash-dotted line) captures other less 
relevant pieces of information, which are common to most of the patients included. A 
quantification of the strength of links among variables is also provided as an overlaid 
numerical coefficient ranging from zero, minimum strength, to 1, maximal strength. 
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Table 1 – Distribution of selected variables at entry in the Psocare registry and analyses of factors associated with biological drug prescription.. 
 Distribution 
N=12,838* 
Univariate analysis Multivariate analysis*** 
n (%) Biologics 
n (%) 
P-value** OR (95% CI) P-value 
Age, yrs (mean, SD) 48.8 (14.4)     
18–29 1247 (9.7%) 428 (34.3%) <0.001 1.12 (0.93–1.51) 0.17 
30–44 3929 (30.6%) 1748 (44.5%) (0.14) 1.34 (1.11–1.62) 0.002 
45–59 4557 (35.5%) 2181 (47.9%)  1.33 (1.12–1.57) 0.001 
≥ 60 3105 (24.2%) 1113 (35.8%)  1  
Gender      
Male 8454 (65.9%) 3626 (42.9%) 0.37   
Female 4384 (34.1%) 1844 (42.1%)    
BMI, kg/m2 (mean, SD) 27.0 (4.9)     
<20.0 485 (4.0%) 186 (38.4%) <0.001 1.00 (0.74–1.34) 0.99 
20.0-24.9 3924 (32.2%) 1572 (40.1%) (<0.001) 1  
25.0-29.9 5088 (41.7%) 2151 (42.3%)  1.15 (1.01–1.32) 0.03 
≥30.0 2696 (22.1%) 1253 (46.5%)  1.27 (1.08–1.49) 0.004 
Smoking habits      
No/Ex 7480 (59.8%) 3269 (43.7%) <0.001 1.22 (1.09–1.38) 0.001 
Yes 5018 (40.2%) 2019 (40.2%)  1  
Drinker      
No/Ex 7851 (64.3%) 3398 (43.3%) 0.001 1.16 (1.03–1.31) 0.02 
Yes, regular 4365 (35.7%) 1753 (40.2%)  1  
Marital status      
Unmarried 2735 (21.6%) 1108 (40.5%) 0.03   
Married/common-law husband/wife 8964 (70.7%) 3878 (43.3%)    
Divorced 567 (4.5%) 247 (43.6%)    
Widowed 407 (3.2%) 158 (38.8%)    
Geographical area of Italy      
Northern 3999 (31.1%) 1342 (33.6%) <0.001 1  
Central/Southern 8839 (68.9%) 4128 (46.7%)  2.42 (2.13–2.75) <0.001 
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 Distribution 
N=12,838* 
Univariate analysis Multivariate analysis*** 
n (%) Biologics 
n (%) 
P-value** OR (95% CI) P-value 
Educational attainment, yrs (mean, SD) 10.3 (3.9)     
0–5 (primary) 2023 (16.0%) 717 (35.4%) <0.001 1  
6–8 (lower secondary) 4214 (33.3%) 1728 (41.0%) (<0.001) 1.13 (0.94–1.35) 0.19 
9–13 (upper secondary) 4926 (38.9%) 2217 (45.0%)  1.35 (1.12–1.62) 0.002 
≥ 14 (higher) 1510 (11.9%) 729 (48.3%)  1.36 (1.07–1.72) 0.01 
Present or last occupation      
Unskilled workers, farmers 1571 (12.4%) 575 (36.6%) <0.001 1  
Employees, craftsmen, skilled workers 4115 (32.5%) 1773 (43.1%)  1.13 (0.93–1.36) 0.23 
Managers, professionals 1111 (8.8%) 572 (51.5%)  1.40 (1.09–1.81) 0.01 
Retired 3212 (25.3%) 1322 (41.2%)  0.90 (0.72–1.11) 0.31 
Housewives, unemployed, students, other 2664 (21.0%) 1149 (43.1%)  1.10 (0.89–1.35) 0.38 
Calendar year of visit      
2005–2006 5061 (39.4%) 2394 (47.3%) <0.001 1   
2007 3333 (26.0%) 1253 (37.6%) (<0.001) 0.84 (0.73–0.96) 0.01 
2008 3073 (23.9%) 1198 (39.0%)  1.09 (0.93–1.27) 0.28 
2009 1371 (10.7%) 625 (45.6%)  1.86 (1.52–2.27) <0.001 
PASI score (mean, SD) 17.2 (10.5)     
<10 1729 (18.8%) 642 (37.1%) <0.001 1  
10–20 4946 (53.7%) 1828 (37.0%) (<0.001) 1.23 (1.05–1.44) 0.01 
> 20 2531 (27.5%) 1326 (52.4%)  1.94 (1.63–2.30) <0.001 
Patient’s perceived severity, VAS (mean, 
SD) 
6.6 (2.6) 
    
0–4 1899 (19.5%) 783 (41.2%) <0.001 1  
5–7 3745 (38.5%) 1572 (42.0%) (<0.001) 1.1 (0.9-1.4)  
8–10 4081 (42.0%) 1899 (46.5%)  1.1 (0.9-1.3)  
Disease duration, yrs (mean, SD) 16.9 (13.0)     
0–4 2341 (18.9%) 634 (27.1%) <0.001   
5–14 3757 (30.4%) 1639 (43.6%) (<0.001)   
15–29 4157 (33.6%) 2050 (49.3%)    
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 Distribution 
N=12,838* 
Univariate analysis Multivariate analysis*** 
n (%) Biologics 
n (%) 
P-value** OR (95% CI) P-value 
≥ 30 2117 (17.1%) 947 (44.7%)    
CCI (mean, SD) 0.29 (0.78)     
0 10812 (84.2%) 4593 (42.5%) 0.76   
1–2 1369 (10.7%) 596 (43.5%)    
> 2 657 (5.1%) 281 (42.8%)    
History of:      
Diabetes      
No 11946 (93.1%) 5074 (42.5%) 0.26   
Yes 892 (6.9%) 396 (44.4%)    
Arterial hypertension      
No 9706 (75.6%) 4015 (41.4%) <0.001 1  
Yes 3132 (24.4%) 1455 (46.5%)  1.20 (1.03–1.38) 0.02 
Hyperlipaemia      
No 11307 (88.1%) 4754 (42.0%) <0.001   
Yes 1531 (11.9%) 716 (46.8%)    
Chronic liver diseases      
No 12404 (96.6%) 5264 (42.4%) 0.04   
Yes 434 (3.4%) 206 (47.5%)    
Neoplasms      
No 12620 (98.3%) 5426 (43.0%) <0.001 4.09 (2.41–6.94)  <0.001 
Yes 218 (1.7%) 44 (20.2%)  1  
Pustular Ps      
No 12469 (97.1%) 5361 (43.0%) <0.001 1.78 (1.25–2.54) 0.001 
Yes 369 (2.9%) 109 (29.5%)  1  
PsA      
No 9655 (75.2%) 3159 (32.7%) <0.001 1  
Yes 3183 (24.8%) 2311 (72.6%)  4.52 (3.94–5.20) <0.001 
No. of previous systemic  
treatments for Ps (mean, SD) 
1.1 (1.2) 
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 Distribution 
N=12,838* 
Univariate analysis Multivariate analysis*** 
n (%) Biologics 
n (%) 
P-value** OR (95% CI) P-value 
0 5442 (42.4%) 889 (16.3%) <0.001 1  
1 3238 (25.2%) 1436 (44.3%) (<0.001) 4.07 (3.53–4.68) <0.001 
2 2530 (19.7%) 1807 (71.4%)  12.46 (10.63–14.60) <0.001 
≥3 1628 (12.7%) 1338 (82.2%)  25.59 (20.73–31.58) <0.001 
Hospital admission for Ps  
in the last 5 yrs 
 
    
No 9030 (70.3%) 3321 (36.8%) <0.001 1  
Yes 3808 (29.7%) 2149 (56.4%)  1.21 (1.06–1.37) 0.004 
Previous clinical remission for Ps      
No 9246 (72.0%) 3708 (40.1%) <0.001 1.18 (1.04–1.35) 0.01 
Yes 3592 (28.0%) 1762 (49.1%)  1  
BMI: body mass index   CCI: Charlson comorbidity index   CI: confidence interval   OR: odds ratio    
PASI: psoriasis area severity index   PsA: psoriatic arthritis 
* Numbers may not add up to the total due to missing data. 
** Pearson’s χ2 test. In the case of ordinal data, when the test was significant (p-value ≤ 0.05), a Cochran–Armitage test for linear trend across different levels of variables 
was also performed. 
*** Independent factors selected in multiple logistic regression analysis with forward stepwise selection algorithm. 
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Table 2 – Univariate and multivariate adjusted analyses of association between educational 
attainment, employment status and severe Ps. 
 Univariate analysis Multivariate analysis** 
PASI score > 20,  
N (%) 
P-value* OR (95% CI) P-value 
Educational attainment, yrs     
0–5 (primary) 467 (31.5%) < 0.001 1.55 (1.34 –1.79) < 0.001 
6–8 (lower secondary) 869 (28.6%) (< 0.001) 1.21 (1.09–1.35) 0.001 
9+ (upper secondary/university) 1125 (24.7%)  1  
Present or last occupation     
Unskilled workers, farmers 300 (26.5%) < 0.001 1.02 (0.82–1.26) 0.86 
Employees, craftsmen, skilled workers 707 (24.0%)  0.89 (0.74–1.06) 0.19 
Managers, professionals 237 (29.3%)  1  
Retired 685 (30.1%)  1.19 (0.98–1.44) 0.07 
Housewives, unemployed, 
students, other 
532 (27.8%)  1.35 (1.11–1.66) 0.004 
CI: confidence interval   OR: odds ratio   PASI: psoriasis area severity index 
* Pearson’s χ2 test. In the case of ordinal data, when the test was significant (p-value ≤ 0.05), a Cochran–
Armitage test for linear trend across different levels of variables was also performed. 
** OR as resulted from multiple logistic regression analyses, including terms for age, gender, BMI and number 
of previous systemic treatments for Ps. 
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Appendix. The Italian Psocare Centres 
 
U.O.C. Dermatologia e Venereologia Ospedale Generale Regionale F. Miulli, 
Acquaviva delle Fonti (V. Griseta, A. Miracapillo); S.O.C. Dermatologia SS. Antonio 
e Biagio e C. Arrigo, Alessandria (M. Azzini, L. Mocci, M. Michelini); U.O. Clinica 
Dermatologica, Ancona (A. Offidani, L. Bernardini, A. Campanati); U.O. 
Dermatologia INRCA/IRCCS, Ancona (G. Ricotti, A. Giacchetti); U.O. Dermatologia 
Ospedale Beauregard, Aosta (M. Norat, F. Gualco); U.O. Dermatologia Ospedale S. 
Donato, Arezzo (A. Castelli, A. Cuccia, A. Diana); S.O.C. Dermatologia Ospedale di 
Asti (G. Roncarolo); U.O. Dermatologia Ospedale S. G. Moscati, Avellino (M.A. Belli, 
M.A. Baldassarre); U.O.C. Dermatologia P.O. Cutroni Zodda, Barcellona (Me.) (G. 
Santoro); U.O. Dermatologia II Azienda Ospedaliera Policlinico Consorziale, Bari 
(G.A. Vena, F. Lo Console, R. Filotico, V. Mastrandrea); U.O. Dermatologica 
Ospedale di Battipaglia (B. Brunetti, F. Musumeci); U.O. di Dermosifilopatia 
Ospedale S. Martino, Belluno (E. Carrabba, P. Dal Mas, F. Annicchiarico, B. 
Benvegnù, G. Spaziani); U.O. Dermatologia Azienda Ospedaliera Rummo, 
Benevento (F. Cusano, S. Saletta Iannazzone ); U.O. Dermatologia Ospedale S. Cuore 
di Gesù Fatebenefratelli, Benevento (A. Galluccio, M. Pezza); USC Dermatologia 
A.O. Ospedali Riuniti di Bergamo (L. Marchesi, G. Imberti, A. Reseghetti); U.O. 
Dermatologia Ospedale degli Infermi, Biella (C. Barbera); U.O. di Dermatologia 
Presidio Ospedaliero Bellaria Maggiore, Bologna (M. Reggiani, A. Lanzoni); U.O. 
Dermatologia Policlinico S. Orsola Malpighi, Bologna (A. Patrizi, F. Bardazzi, A. 
Antonucci, S. De Tommaso, R. Balestri); Divisione dermatologica Bolzano, Bolzano 
(W. Wallnofer, F. Ingannamorte); Divisione Dermatologica, Azienda Spedali Civili di 
Brescia (P. Calzavara-Pinton, S. Iannazzi, C. Zane, R. Capezzera, S. Bassisi, M.T. 
Rossi); U.O. complessa di Dermatologia P.O. Perrino, Brindisi (V. Altamura); U.O. 
Dermatologia Ospedale di Brunico (W. Vigl, C. Nobile); Clinica Dermatologica 
Università di Cagliari (N. Aste, S. Murgia, C. Mugheddu); U.O. Dermatologia A.O. 
Ospedale S. Elia, Caltanissetta (G. Scuderi, F. Baglieri, C. Di Dio); U.O. Dermatologia 
Ospedale B. Eustachio, Camerino (E. Cilioni Grilli); U.O. Dermatologia P.O. 
Cardarelli, Campobasso (C. Mastronardi, C.P. Agnusdei, A. Antrilli); S.O.C. 
Dermatologia Ospedale Casale Monferrato (L. Aulisa); U.O. Dermatologia A.O. San 
Sebastiano, Caserta (U. Raimondo, G. Scotto di Luzio, V.C. Battarra, P. Farro, R. 
Plaitano); Clinica Dermatologica, Università di Catania A.O. V. Emanuele, Catania 
(G. Micali, M.L. Musumeci, D. Massimino, M. Li Calzi); U.O. Dermatologia A.O. 
Garibaldi S. L. Currò A. Tomaselli, Catania (S. La Greca); U.O.C. di Dermatologica 
A.O. Universitaria V. Emanuele, Catania (M. Pettinato, G. Sapienza); U.O. Dermatolo 
gia A.O. Pugliese Ciaccio, Catanzaro (G. Valenti, P.F. De Giacomo, D. d’Amico); 
U.O. Dermatologia Ospedale di Cesena (F. Arcangeli, D. Brunelli, E. Ghetti); Clinica 
Dermatologica, Università di Chieti (A. Tulli, G. Assi, P. Amerio); U.S. Complessa di 
Dermosifilopatia Ospedale S. Anna, Como (G. Laria, F. Prestinari); U.O. 
Dermatologia P.O. Mariano Santo, Cosenza (S. Spadafora, M. Coppola); Istituti 
Ospitalieri di Cremona Servizio Ospedaliero di Dermatologia, Cremona (G. 
Caresana, E. Pezzarossa, E. Domaneschi, C. Felisi); U.O. Dermatologia P.O. Crotone 
(L. Donato); S.O.C. Dermatologia Ospedale Santa Croce e Carle, Cuneo (M. Bertero, 
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L. Musso, S. Pa lazzini,); U.O. Dermatologia Ospedale S. Verdiana, Empoli (P. 
Bruscino); U.O. di Dermatologia e M.S.T. A.O. U I, Enna (U.C. Agozzino); U.O. 
Dermatologia Ospedale Civile di Fabriano (M. Ottaviani, C. Simoncini); Sezione di 
Dermatologia Azienda Ospedaliera Universitaria Ferrara (A. Virgili, F. Osti); Dip. 
Scienze Dermatologiche Università di Firenze (P. Fabbri, W. Volpi, M. Caproni); 
U.O. Complessa Dermatologica di Fisioterapia Dermatologica, Firenze (T. Lotti, F. 
Prignano, G. Buggiani, M. Troiano); U.O. Dermatologia Azienda Ospedaliero- 
Universitaria, Foggia (G. Fenizi, A. Altobella, A. Amoruso, M. Condello, A. 
Goffredo); U.O. Dermatologia Ospedale G.B. Morgagni- L. Pieranto, Forlì (M.G. 
Righini, F. Alessandrini, F. Satolli); Azienda USL Roma H U.O.C. Dermatologia 
Aziendale Ospedale di Frascati (M. Zampetti); U.O. Dermatologia A.O. S. A. Abate, 
Gallarate (E. Bertani, S. Fossati); Di.S.E.M. Sezione di Dermatologia, Genova (A. 
Parodi, M. Burlando, C. Fiorucci); U.O. Dermatologia Ospedale S. Martino, Genova 
(A. Nigro, G. Ghigliotti); U.O. complessa di Dermatologia dell’Ente Ospedaliero 
Galliera, Genova (L. Massone); SOC Dermatologia Azienda per i Servizi Sanitari n. 2 
Isontina, Gorizia (G.M. Moise); U.O. Dermatologia Presidio Ospedaliero 
Misericordia, Grosseto (M. Serrai); U.O. complessa di Dermatologia Ospedale Civile, 
Imperia (G. Cannata, A.M. Campagnoli); U.O. Dermatologia Ospedali Riuniti di 
Ivrea (M. Daly, C. Leporati, R. Peila); U.O. Dermatologia Ospedale A. Murri, Jesi (G. 
Filosa, L. Bugatti, M. Nicolini); U.O. di Dermatologia Ospe dale Civile Sant’Anna, La 
Spezia (G. Nazzari, R. Cestari); U.O. Dermatologia Ospedale Civile, Lamezia Terme 
(F. Anastasio, F.M. Larussa); Reparto di Dermatologia Ospedale di Lanciano, 
Lanciano (N. Pollice, F. De Francesco, G. Mazzocchetti); Dermatologia Oncologica e 
Molecolare, L’Aquila (K. Peris, M.C. Fargnoli, A. Di Cesare, L. De Angelis); U.O.C. 
Dermatologia Ospedale Regionale S. Salvatore, L’Aquila (G. Flati, A.S. Biamonte); 
U.O. Dermatologia Ospedale V. Fazzi Lecce (G. Quarta, M. Congedo); Dermatologia 
Presidio A. Manzoni, Lecco (A. Carcaterra, D. Strippoli, D. Fideli); U.O.C. 
Dermatologia Ospedale Versilia, Lido di Camaiore (F. Marsili, M. Celli); U.O. 
Dermatologia Ospedali Riuniti di Livorno (M. Ceccarini, L. Bachini, M. D’Oria); P.O. 
Siderno ASL9 Locri (V. Schirripa); U.O. Dermatologia A.O. della provincia di Lodi 
(C. De Filippi); U.O. Dermatologia Ospedale Campo di Marte, Lucca (P. Martini, E. 
Lapucci, C. Mazzatenta, A. Ghilardi); U.O. di Dermatologia Ospedale di Macerata, 
Macerata (M. Simonacci, A. Bettacchi, R. Gasco); U.O. Dermatologia Ospedale. S. 
Carlo Poma, Mantova (A. Zanca); U.O. Dermatologia P.O. Massa (S. Battistini); 
Servizio Dermatologia P.O. Melito Porto Salvo, Melito (S. Dattola, R. Vernaci, F. 
Postorino); Divisione dermatologia e venerologia Ospedale Franz Tappeiner, 
Merano (P.F. Zampieri, C. Padovan, M.A. González Intchaurraga, J. Ladurner); 
U.O.C. di Dermatologia A.O.U. G. Martino, Messina (B. Guarneri, S. Cannavò, C. 
Manfrè, F. Borgia); U.O. Dermatologia A.O. Papardo, Messina (A. Puglisi Guerra); 
U.O. Dermatologia Dermatologia Ospedale Umberto I, Mestre (P. Sedona); Centro 
per lo studio e la cura della psoriasi IRCCS Ospedale Maggiore di Milano U.O. di 
dermatologia, Milano (A. Cattaneo, C. Carrera, C. Fracchiolla, N. Mozzanica, L. 
Prezzemolo); Clinica Dermatologica Universitaria AO San Paolo, Milano (S. Menni, 
A. Lodi, P. Martino); U.O. Dermatologia Istituto Clinico Humanitas, Milano (M. 
Monti, L. Mancini, F. Sacrini); Servizio di Dermatologia Istituto Ortopedico Galeazzi, 
Milano (G.F. Altomare, M. Taglioni, C. Lovati); Dermatologia IRCCS Fondazione 
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Centro San Raffaele del Monte Tabor, Milano (S.R. Mercuri); U.O. di Dermatologia 
Ospedale di Mirano, Mirano (G. Schiesari); Clinica Dermatologica di Modena, 
Modena (A. Giannetti, A. Conti, C. Lasagni, M. Greco, G. Ronsini, S. Schianchi, C. 
Fiorentini, S. Niglietta, R. Maglietta, C. Padalino); U.S.C. di Dermosifilopatia A.O. 
San Gerardo, Monza (D. Crippa, M. Pini, E. Rossi, D. Tosi, M. Armas); U.O. di 
Clinica Dermatologica, Napoli (V. Ruocco); Sezione di dermatologia dipartimento di 
patologia sistematica, Napoli (F.Ayala, N. Balato, F. Gaudiello, G.F. Cimmino, G. 
Monfrecola, L. Gallo); D.A.S. Dermatologia e Venereologia, U.O. Malattie Veneree e 
Dermatologia Parassitaria, Seconda Università di Napoli (G. Argenziano, E. 
Fulgione); U.O.C. di Dermatologia P.O. SanGennaro, Napoli (G. Berruti); DH 
dermatologico P.O. Ascalesi, Napoli (S. Ceparano, I. De Michele); U.O. Dermatologia 
P.O. Tortora Pagani, Nocera Pagani (D. Giorgiano); Clinica dermatologica Università 
del Piemonte Orientale c/o Ospedale maggiore della carità, Novara (G. Leigheb); 
U.O. Dermatologia Ospedale S.F. Nuoro, Nuoro (S. Deledda); Clinica dermatologica 
Università di Padova, Padova (A. Peserico, M. Alaibac, S. Piaserico, L. Schiesari, G. 
Dan, I. Mattei, E. Oro); Cattedra di dermatologia-UOC di dermatologia e malattie 
sessualmente trasmesse Policlinico P. Giaccone Palermo (M. Aricò, M.R. Bongiorno, 
R. Angileri); U.O. di Dermatologia ARNAS Civico-Di Gristina-M. Ascoli, Palermo 
(S.Amato, F. Todaro, M. Milioto, R. Bellastro); Centro di fotodermatologia, Parma (S. 
Di Nuzzo, G. De Panfilis, M. Zanni); Clinica Dermatologica Università di Pavia 
IRCCS Policlinico S. Matteo, Pavia (G. Borroni, R. Cananzi, V. Brazzelli); Sezione di 
Dermatologia clinica, allergologica e venereologica, Dipartimento di Specialità 
medico-chirurgiche e Sanità pubblica, Università di Perugina (P. Lisi, L. Stingeni, K. 
Hansel); U.O. Dermatologia Ospedale Civile Pescara (V. Pierfelice); U.O. Semplice 
Dipartimentale di Dermatologia Ospedale Piacenza (S. Donelli, D. Rastelli, M. 
Gasperini); U.O. Dermatologia Azienda Ospedaliera Pisana, Pisa (P. Barachini); U.O. 
Dermatologia – Ospedale di Pistoia, Pistoia (R. Cecchi, L. Bartoli, M. Pavesi); U.O. 
Semplice Dermatologia Ospedale di Polla e S. Arsenio, Polla (S. De Paola); U.O. 
Dermatologia Azienda Ospedaliera Santa Maria degli Angeli, Pordenone (M.T. 
Corradin); U.O. Dermatologia Centro MTS, Potenza (F. Ricciuti, A. Piccirillo, L. 
Viola, M. Tataranni, M.G. Mautone); U.O. Dermatologia Ospedale Misericordia e 
Dolce, Prato (G. Lo Scocco, M.C. Niccoli, A.M.G. Brunasso Vernetti); U.O. Aziendale 
di Dermatologia di Ravenna, Ravenna (G. Gaddoni, F. Resta, M.C. Casadio); U.O. 
Dermatologia Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria 
(M.C. Arcidiaco, M.C. Luvarà); Struttura Complessa di Dermatologia Azienda 
Ospedaliera Arcispedale, Reggio Emilia (G. Albertini, V. Di Lernia, E. Guareschi); 
U.O. Dermatologia Ospedale Infermi, Rimini (S. Catrani, M. Morri); Clinica 
Dermatologica Policlinico Gemelli, Roma (P.Amerio, C. De Simone, M. D’Agostino, 
I. Agostino); Dip. Malattiecutanee-Veneree e Chiurgia Plastica-ricostruttiva 
Università studi di Roma, Roma (S. Calvieri, F. Cantoresi, A. Richetta, P. Sorgi, C. 
Carnevale, F. Nicolucci); Istituto Dermatologico S. Gallicano, Roma (E. Berardesca, 
M. Ardigò, C. De Felice); IDI IRCCS, Roma (E. Gubinelli); Clinica Dermatologica, 
Università Studi di Roma, Roma (S. Chimenti, M. Talamonti); U.O. Dermatologia 
Azienda Ospedaliera Sant’Andrea, Roma (G. Camplone); U.O. Dermatologia 
Azienda Ospedaliera San Camillo Forlanini, Roma (G. Cruciani, F. Riccardi); U.O. 
Dermatologia Ospedale S. Eugenio, Roma (R. Barbati); U.O. Dermatologia Ospedale 
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S. Maria del Carmine, Rovereto (G. Zumiani); S.O.C. Dermatologia Ospedale Civico, 
Rovigo (W. Pagani); Ambulatorio di Dermatologia Policlinico San Donato, S. Donato 
Milanese (P.G. Malagoli); U.O. Dermatologia IRCCS Casa Sollievo della Sofferenza, 
S. Giovanni Rotondo (R. Pellicano); U.O.C. Dermatologia Ospedale S. Giovanni Di 
Dio, Salerno (D. Donadio, C. Di Vito); Clinica Dermatologica Università di Sassari, 
Sassari (F. Cottoni, M.A. Montesu, C. Pirodda, G. Addis, P. Marongiu); U.O. di 
Dermatologia Ospedale San Paolo, Savona (A. Farris, M. Cacciapuoti, A. Verrini); 
U.O. di Dermatologia Ospedale Civile di Sestri Levante, Sestri Levante (G. Desirello, 
M. Gnone); Azienda Ospedaliera Senese D.A.I. Medicina Clinica e Scienze 
Immunologiche applicate S.C. di dermatologia, Siena (M. Fimiani, M. Pellegrino); 
U.O.C. di Dermatologia A.O. U I, Siracusa (G. Castelli, L. Zappalà); Dermatologia 
A.O. della Valtellina e della Valchiavenna, Sondrio (G. Sesana); Ospedale Marina 
Militare Taranto Rep. Dermatologia, Taranto (V. Ingordo); U.O. Complessa di 
Dermatologia e Chirurgia Dermatologica, Taranto (E. Vozza, D. Di Giuseppe); U.O. 
Dermatologia P.O. G. Mazzini, Teramo (D. Fasciocco, P. Nespoli); Clinica 
Dermatologica 
di Terni, Terni (M. Papini, M. Cicoletti); SCDU Dermosifilopatia 2 Ospedale S. 
Lazzaro, Torino (M.G. Bernengo, M. Ortoncelli, A. Bonvicino, G. Capella, G.C. 
Doveil, M. Forte, A. Peroni, B. Salomone, P. Savoia); SCDU Dermosifilopatia 3 
Ospedale S. Lazzaro, Torino (M. Pippione); U.O. Dermatologia Azienda Ospedaliera 
S. A. Abate, Trapani (L. Zichichi, M. Frazzitta, G. De Luca); U.O. Dermatologia 
Ospedale S. C. di Trento, Trento (G. Zumiani, L. Tasin); U.O. di dermatologia 
ospedale Cà Foncello, Treviso (D. Simonetto, S. Ros); Istituto di Clinica 
Dermatologica, Trieste (G. Trevisan, M. Patamia, S. Miertusova); Clinica 
Dermatologica, Udine (P. Patrone, A. Frattasio, F. Piccirillo, S. La Spina, L. Di 
Gaetano); S.O.C. Dermatologia Azienda Ospedaliera Santa Maria della Misericordia 
di Udine (Udine, V. Marzocchi); U.O. Dermatologia Ospedale II Circolo, Varese (A. 
Motolese, C. Venturi); U.O. Dermatologia Venezia Mestre Ospedale SS. Giovanni e 
Paolo, Venezia (P. Sedona, F. Gai, S. Pasquinucci); S.O.C. Dermatologia Ospedale di 
Vercelli, Vercelli (R.M. Bellazzi, T. Silvestri); Clinica dermatologica Ospedale Civile 
Maggiore, Verona (G. Girolomoni, P. Gisondi); U.O. Dermatologia Vicenza (C. Veller 
Fornasa, G.P. Trevisan). 
 
 
 
